Click here for Canada websiteHistoric Milestones
2022
January 2022
Covis Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZeneca
2020
November 2020
Covis Group completes acquisition of AMAG Pharmaceuticals along with the global rights for Makena® and Feraheme®.
February 2020
Funds managed by affiliates of Apollo Global Management acquired Covis Pharma from Cerberus.
2018
November 2018
Acquired global rights for Alvesco®, Omnaris®, and Zetonna®.
2017
July 2017
Acquired the U.S. marketing and distribution rights for Alvesco®, Omnaris®, and Zetonna®.
April 2017
Acquired the U.S. marketing and distribution rights for Prilosec® Packets.
2016
November 2016
Acquired the U.S. marketing and distribution rights for Sular®.
2015
May 2015
Acquired the U.S. marketing and distribution rights for Altoprev®.
April 2015
Divested majority of product assets to Concordia Healthcare Corp in a deal valued at $1.2 billion.
January 2015
Acquired the U.S. marketing and distribution rights for Betapace® & Betapace AF®.
2014
October 2014
Acquired the U.S. marketing and distribution rights for Dibenzyline® and Dyrenium®.
Entered into authorized generic agreement with Prasco for several brands.
February 2014
Acquired the U.S. marketing and distribution rights for DuToprol®.
January 2014
Initiated funding of cardiology sales force for U.S. distribution partner to promote Lanoxin®.
2013
December 2013
Entered into authorized generic agreement with Par Pharmaceuticals for Lanoxin®.
October 2013
Received FDA approval for the alternative dosage strengths of Lanoxin®.
June 2013
Entered into authorized generic agreement with Rising Pharmaceuticals for Rilutek®.
April 2013
Acquired the U.S. marketing and distribution rights for Kayexalate®, Nilandron®, Plaquenil®, Rilutek®, and Uroxatral® from Sanofi.
2012
October 2012
Entered into authorized generic agreement with Rising Pharmaceuticals for Parnate®.
January 2012
Initiated development of alternative dosage strengths of Lanoxin®.
2011
December 2011
Acquired the U.S. marketing and distribution rights for Lanoxin®, Lanoxin® IV Parnate®, Zantac®, Fortaz® and Zinacef® from GlaxoSmithKline.
April 2011
Founded by Cerberus Capital Management, the investment management firm with over $30 billion in assets under management.